Fig. 1: Compound library screening identifies nitroxoline as a novel inhibitor of pyroptosis.
From: Nitroxoline is a novel inhibitor of NLRP3-dependent pyroptosis
A Workflow for target identification screening of the Selleckchem Bioactive Compound Library and Spectrum library, comprising 6280 drugs, drug-like compounds, and natural compounds. B Exemplary results of the screening of a 384-well plate. Propidium iodide (PI) fluorescence of THP-1 ASC-GFP cells after drug treatment and incubation with 1 µg ml−1 LPS (4 h) and 5 µg ml−1 nigericin (1 h), assayed at 20 µM for each compound. Propidium iodide fluorescence intensity difference to mean is presented. Nitroxoline is shown in red. C Concentration-response curve of LPS- and nigericin-treated THP-1 cells depicting propidium iodide (PI) fluorescence at the indicated compound concentrations. DMSO volume was adjusted to that of nitroxoline (n = 6). D Cell viability was analyzed using the CellTiter-Glo assay of nitroxoline-treated THP-1 WT cells at the indicated concentrations. The volume of DMSO was adjusted to nitroxoline concentrations (n = 3). E: IL-1β release from THP-1 WT cells treated with LPS and nigericin with the addition of 80 µM nitroxoline or equal volume of DMSO as solvent control (n = 4). Data are presented as mean + SD. Data were analyzed using the Student’s t-test. *p < 0.05.
